421 related articles for article (PubMed ID: 28102887)
1. Clinical trial of nintedanib in patients with recurrent or metastatic salivary gland cancer of the head and neck: A multicenter phase 2 study (Korean Cancer Study Group HN14-01).
Kim Y; Lee SJ; Lee JY; Lee SH; Sun JM; Park K; An HJ; Cho JY; Kang EJ; Lee HY; Kim J; Keam B; Kim HR; Lee KE; Choi MY; Lee KH; Ahn MJ
Cancer; 2017 Jun; 123(11):1958-1964. PubMed ID: 28102887
[TBL] [Abstract][Full Text] [Related]
2. A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: Translational analyses and clinical impact.
Locati LD; Perrone F; Cortelazzi B; Bergamini C; Bossi P; Civelli E; Morosi C; Lo Vullo S; Imbimbo M; Quattrone P; Dagrada GP; Granata R; Resteghini C; Mirabile A; Alfieri S; Orlandi E; Mariani L; Saibene G; Pilotti S; Licitra L
Eur J Cancer; 2016 Dec; 69():158-165. PubMed ID: 27821319
[TBL] [Abstract][Full Text] [Related]
3. A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland Cancer.
Rodriguez CP; Wu QV; Voutsinas J; Fromm JR; Jiang X; Pillarisetty VG; Lee SM; Santana-Davila R; Goulart B; Baik CS; Chow LQM; Eaton K; Martins R
Clin Cancer Res; 2020 Feb; 26(4):837-845. PubMed ID: 31796519
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and toxicity of sorafenib in patients with adenoid cystic carcinoma of the head and neck: a case series of five patients.
Couvreur K; Celine J; Marlies B; Randal D; Philippe D; Frederic D; Sylvie R
Acta Clin Belg; 2020 Oct; 75(5):362-369. PubMed ID: 31232197
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors.
Wong SJ; Karrison T; Hayes DN; Kies MS; Cullen KJ; Tanvetyanon T; Argiris A; Takebe N; Lim D; Saba NF; Worden FP; Gilbert J; Lenz HJ; Razak AR; Roberts JD; Vokes EE; Cohen EE
Ann Oncol; 2016 Feb; 27(2):318-23. PubMed ID: 26598548
[TBL] [Abstract][Full Text] [Related]
6. Phase 2 study of dovitinib in patients with metastatic or unresectable adenoid cystic carcinoma.
Keam B; Kim SB; Shin SH; Cho BC; Lee KW; Kim MK; Yun HJ; Lee SH; Yoon DH; Bang YJ
Cancer; 2015 Aug; 121(15):2612-7. PubMed ID: 25903089
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of taxol in salivary gland malignancies (E1394): a trial of the Eastern Cooperative Oncology Group.
Gilbert J; Li Y; Pinto HA; Jennings T; Kies MS; Silverman P; Forastiere AA
Head Neck; 2006 Mar; 28(3):197-204. PubMed ID: 16470745
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of nintedanib in patients with bevacizumab-resistant recurrent epithelial ovarian, tubal, and peritoneal cancer.
Secord AA; McCollum M; Davidson BA; Broadwater G; Squatrito R; Havrilesky LJ; Gabel AC; Starr MD; Brady JC; Nixon AB; Duska LR
Gynecol Oncol; 2019 Jun; 153(3):555-561. PubMed ID: 30929823
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial with axitinib in recurrent and/or metastatic salivary gland cancers of the upper aerodigestive tract.
Locati LD; Cavalieri S; Bergamini C; Resteghini C; Alfieri S; Calareso G; Bossi P; Perrone F; Tamborini E; Quattrone P; Granata R; Galbiati D; Platini F; Orlandi E; Mariani L; Licitra L
Head Neck; 2019 Oct; 41(10):3670-3676. PubMed ID: 31355973
[TBL] [Abstract][Full Text] [Related]
10. A phase II study of sunitinib in recurrent and/or metastatic adenoid cystic carcinoma (ACC) of the salivary glands: current progress and challenges in evaluating molecularly targeted agents in ACC.
Chau NG; Hotte SJ; Chen EX; Chin SF; Turner S; Wang L; Siu LL
Ann Oncol; 2012 Jun; 23(6):1562-70. PubMed ID: 22080184
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of gefitinib in patients with advanced salivary gland cancers.
Jakob JA; Kies MS; Glisson BS; Kupferman ME; Liu DD; Lee JJ; El-Naggar AK; Gonzalez-Angulo AM; Blumenschein GR
Head Neck; 2015 May; 37(5):644-9. PubMed ID: 24585506
[TBL] [Abstract][Full Text] [Related]
12. A Single-Arm, Prospective, Phase II Study of Cisplatin Plus Weekly Docetaxel as First-Line Therapy in Patients with Metastatic or Recurrent Salivary Gland Cancer.
Kim HR; Lee SJ; Park S; Jung HA; Lee SH; Jeong HS; Chung MK; Ahn MJ
Cancer Res Treat; 2022 Jul; 54(3):719-727. PubMed ID: 34727492
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of single-agent foretinib (GSK1363089) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
Seiwert T; Sarantopoulos J; Kallender H; McCallum S; Keer HN; Blumenschein G
Invest New Drugs; 2013 Apr; 31(2):417-24. PubMed ID: 22918720
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands.
Agulnik M; Cohen EW; Cohen RB; Chen EX; Vokes EE; Hotte SJ; Winquist E; Laurie S; Hayes DN; Dancey JE; Brown S; Pond GR; Lorimer I; Daneshmand M; Ho J; Tsao MS; Siu LL
J Clin Oncol; 2007 Sep; 25(25):3978-84. PubMed ID: 17761983
[TBL] [Abstract][Full Text] [Related]
15. Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study.
Hotte SJ; Winquist EW; Lamont E; MacKenzie M; Vokes E; Chen EX; Brown S; Pond GR; Murgo A; Siu LL
J Clin Oncol; 2005 Jan; 23(3):585-90. PubMed ID: 15659505
[TBL] [Abstract][Full Text] [Related]
16. A Phase II Trial of Nintedanib in Patients with Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma: In-Depth Analysis of Nintedanib Arm from the KCSG HN 15-16 TRIUMPH Trial.
Kim KH; Lim SM; Ahn HK; Lee YG; Lee KW; Ahn MJ; Keam B; Kim HR; Lee HW; An HJ; Kim JS
Cancer Res Treat; 2024 Jan; 56(1):37-47. PubMed ID: 37475136
[TBL] [Abstract][Full Text] [Related]
17. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.
Vermorken JB; Stöhlmacher-Williams J; Davidenko I; Licitra L; Winquist E; Villanueva C; Foa P; Rottey S; Skladowski K; Tahara M; Pai VR; Faivre S; Blajman CR; Forastiere AA; Stein BN; Oliner KS; Pan Z; Bach BA;
Lancet Oncol; 2013 Jul; 14(8):697-710. PubMed ID: 23746666
[TBL] [Abstract][Full Text] [Related]
18. Excessive toxicity of cabozantinib in a phase II study in patients with recurrent and/or metastatic salivary gland cancer.
van Boxtel W; Uijen MJM; Krens SD; Dijkema T; Willems SM; Jonker MA; Pegge SAH; van Engen-van Grunsven ACH; van Herpen CML
Eur J Cancer; 2022 Jan; 161():128-137. PubMed ID: 34920917
[TBL] [Abstract][Full Text] [Related]
19. Patients with adenoid cystic carcinomas of the salivary glands treated with lenvatinib: Activity and quality of life.
Locati LD; Galbiati D; Calareso G; Alfieri S; Singer S; Cavalieri S; Bergamini C; Bossi P; Orlandi E; Resteghini C; Platini F; Granata R; Quattrone P; Mancinelli M; Mariani L; Lo Vullo S; Licitra LF
Cancer; 2020 Jan; 126(9):1888-1894. PubMed ID: 32031693
[TBL] [Abstract][Full Text] [Related]
20. A phase 2 trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck: a trial of the Eastern Cooperative Oncology Group (E1303).
Argiris A; Ghebremichael M; Burtness B; Axelrod RS; Deconti RC; Forastiere AA
Cancer; 2011 Aug; 117(15):3374-82. PubMed ID: 21246525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
